@article {Watson2020.04.24.20078303, author = {James A Watson and Joel Tarning and Richard M Hoglund and Frederic J Baud and Bruno M{\'e}garbane and Jean-Luc Clemessy and Nicholas J White}, title = {Concentration-dependent mortality of chloroquine in overdose}, elocation-id = {2020.04.24.20078303}, year = {2020}, doi = {10.1101/2020.04.24.20078303}, publisher = {Cold Spring Harbor Laboratory Press}, abstract = {Hydroxychloroquine and chloroquine are used extensively in malaria and rheumatological conditions, and now in COVID-19 prevention and treatment. Although generally safe they are potentially lethal in overdose. In-vitro data suggest that high concentrations and thus high doses are needed for COVID-19 infections, but as yet there is no convincing evidence they are clinically effective. Bayesian regression models were fitted to survival outcomes and electrocardiograph QRS durations from 302 prospectively studied French patients who had taken intentional chloroquine overdoses, of whom 33 died (11\%), and 16 healthy volunteers who took 620 mg base chloroquine single doses. Whole blood concentrations of 13.5 μmol/L (95\% credible interval 10.1-17.7) were associated with 1\% mortality. Prolongation of ventricular depolarisation is concentration-dependent with a QRS duration \>150 msec independently highly predictive of mortality. Pharmacokinetic modelling combined with these lethality data predicts that the majority of chloroquine regimens trialled in COVID-19 should not cause serious cardiovascular toxicity.Competing Interest StatementThe authors have declared no competing interest.Funding StatementWellcome Trust of Great Britain and the Bill and Melinda Gates Foundation.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This a retrospective analysis of previously published data.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data are available on the github repository linked in the manuscript. https://github.com/jwatowatson/Chloroquine-concentration-fatality}, URL = {https://www.medrxiv.org/content/early/2020/06/16/2020.04.24.20078303}, eprint = {https://www.medrxiv.org/content/early/2020/06/16/2020.04.24.20078303.full.pdf}, journal = {medRxiv} }